Arm 3
Arm 3 is a pharmaceutical drug with 8 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
4 of 4 finished
0.0%
0 ended early
2
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer
Maternal Mental Health Access - MaMa
Brighter Bites & UT Physicians Produce Rx Program
Evaluation of Positioning Protocols on a Wheelchair in Hemiplegic Patients
tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella)
Clinical Trials (8)
Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer
Maternal Mental Health Access - MaMa
Brighter Bites & UT Physicians Produce Rx Program
Evaluation of Positioning Protocols on a Wheelchair in Hemiplegic Patients
tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella)
Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study
Study of of URC102 to Assess the Efficacy and Safety in Gout Patients
Increasing Colorectal Cancer Screening Among Filipino Americans
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8